USC-Norris Cancer Center

Phase	Trial	Trial Status	Site Status [desc]	Drug	NCT#
3	Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)	Active, not recruiting	Closed	QINLOCK Ripretinib DCC-2618	NCT03353753
2	Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate	Ongoing, but not recruiting	Closed	Sorafenib (Nexavar, BAY 43-9006)	NCT00265798
5	Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors	Recruiting	Available	Bezuclastinib	NCT06948955
1/2	A Study of DCC-3116 in Combination with Anticancer Therapies in Participants with Advanced Malignancies	Recruiting	Active	DCC-3116 + Ripretinib	NCT05957367
2	KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting	Recruiting	Active	KQB198 + Imatinib	NCT07406633
1	A Study of Ziftomenib, an Oral Menin Inhibitor, in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)	Recruiting	Active	Ziftomenib + Imatinib	NCT06655246